MetaCap

AbCellera Biologics (ABCL) vs Viridian Therapeutics (VRDN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbCellera Biologics (ABCL) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 176.1% versus a loss of 1.3%. Over five years, VRDN leads with a +63.7% price change compared with -30.7% for ABCL. Viridian Therapeutics is the larger company by market cap ($3.40 billion vs $3.16 billion), about 1.1 times the size.

AbCellera Biologics converts more of its revenue into profit, with a net margin of -194.9% versus -483.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABCL+176.07%VRDN-1.25%
+341%+133%-75%
Nov 21, 20251 yearNov 20, 2026
ABCL-38.67%VRDN+54.04%
+102%+3%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABCL versus VRDN key metrics
MetricABCLVRDN
Share price$9.69$29.96
Market cap$3.16B$3.40B
1-day change-7.45%-4.71%
YTD return+183.33%-3.73%
1-year return+176.07%-1.25%
5-year return-30.74%+63.72%
EPS (TTM)$-0.48$-3.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.13M$70.85M
Revenue growth (YoY)+160.56%+23359.93%
Net income (latest FY)$-146.41M$-342.60M
Operating margin-288.98%-512.91%
Net margin-194.88%-483.57%
52-week high$15.02$34.29
52-week low$2.75$13.18
Distance from 52-week high-35.46%-12.63%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+92.67%+42.72%
Average volume4.34M2.14M
Shares outstanding326.62M113.56M
Employees562252
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABCL has outperformed VRDN by 177.3 percentage points over the past year.
  • AbCellera Biologics is more profitable, keeping -194.9 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
  • Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +160.56%).

About AbCellera Biologics

ABCL stock →

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees

About Viridian Therapeutics

VRDN stock →

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees

ABCL vs VRDN FAQ

Which is bigger, AbCellera Biologics or Viridian Therapeutics?

Viridian Therapeutics (VRDN) is larger, with a market capitalization of $3.40B compared with $3.16B for AbCellera Biologics (ABCL).

Which stock has performed better over the past year, ABCL or VRDN?

ABCL returned +176.07% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.

Are AbCellera Biologics and Viridian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons